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Abstract
Background
Visceral leishmaniasis (VL) is a neglected parasitic disease that is fatal if left untreated. VL
is endemic in Morocco and other countries in North Africa were it mainly affects children
from rural areas. In Morocco, the direct observation of Leishmania parasites in bone marrow
aspirates and serological tests are used to diagnose VL. Glucantime is the first line of treat-
ment. The objective of this study was to report the costs associated to standard clinical man-
agement of pediatric VL from the provider perspective in Morocco. As a secondary
objective we described the current clinical practices and the epidemiological characteristics
of pediatric VL patients.
Methods
From March to June 2014 we conducted a survey in eight hospitals treating pediatric VL
patients in Morocco. A pro-forma was used to collect demographic, clinical and manage-
ment data from medical records. We specifically collected data on VL diagnosis and treat-
ment. We also estimated the days of hospitalization and the time to start VL treatment.
Costs were estimated by multiplying the use of resources in terms of number of days in hos-
pital, tests performed and drugs provided by the official prices. For patients receiving part of
their treatment at Primary Health Centers (PHC) we estimated the cost of administering the
Glucantime as outpatient. We calculated the median cost per VL patient. We also estimated
the cost of managing a VL case when different treatment strategies were applied: inpatient
and outpatient.
Results
We obtained data from 127 VL patients. The median total cost per pediatric VL case in
Morocco is 520 US$. The cost in hospitals applying an outpatient strategy is significantly
lower (307 US$) than hospitals keeping the patients for the whole treatment (636 US$).
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However the outpatient strategy is not yet recommended as VL treatment for children in the
Moroccan guidelines. VL diagnosis and treatment regimens should be standardized follow-
ing the current guidelines in Morocco.
Introduction
Visceral leishmaniasis (VL), also known as kala-azar, is a neglected parasitic disease transmit-
ted by sand flies. VL is usually fatal if not treated and causes 20 to 40 thousand deaths per year
worldwide [1]. In North African countries VL is caused by Leishmania infantum and affects
primarily children living in poor rural areas with limited access to diagnostic and treatment.
In Morocco, leishmaniasis is a priority for the Ministry of Health due to their public health
and economic impact [2]. VL is endemic in the northern regions but sporadic cases are
reported in the South of the country [3]. Over 150 VL cases are reported per year in Morocco
[3], however this figure is suspected to be a fraction of the real burden of the disease. Some
authors estimated that the VL incidence may be as high as 600 cases per year [1]. In Morocco
VL patients are usually below 5 years old and present the triad of splenomegaly, fever and pan-
cytopenia in most of the cases [4–6]. Fever is usually associated with rigor and chills and may
be intermittent and irregular. Loss of appetite, pallor, weight loss and weakness are also com-
mon in VL patients [4–6].
In Morocco VL is diagnosed based on a combination of clinical signs (e.g. fever>2 weeks)
with parasitological and/or serological (Immunofluorescence (IFI) or ELISA) tests in patients
coming from endemic areas [2]. The parasitological confirmation involves visualizing Leish-
mania parasites in bone marrow, spleen or lymph node aspirates. The parasitological test,
which remains the gold standard, requires an invasive and painful procedure (e.g. sternal aspi-
ration in children) and trained laboratory personnel. The serological tests currently applied
also require laboratory facilities and expertise limiting the VL diagnostic capacity to tertiary
care hospitals in Morocco. Rapid diagnostic tests (e.g. rk39 dipstick) extensively used in other
VL endemic areas [7] are not currently used in Morocco. Meglumine antimoniate (Glucan-
time) remains the first line treatment for pediatric VL in Morocco. Glucantime, which is not
available at private pharmacies, is included in the National Essential Drug List. According to
the national guidelines, this treatment (20 mg of pentavalent antimonial (Sbv)/kg for 20 days)
requires close clinical monitoring [2]. In Morocco the fatality rate of VL patients treated with
Glucantime range from 1 to 4% [3,4,6,7]. Liposomal amphotericin B (Ambisome) is the second
line of treatment but it is rarely used [2].
In Morocco, despite the relevance of pediatric VL in some areas, the burden of this disease
is not well known. Most of the costs associated to VL management are covered by the Ministry
of Health (MoH) as medical care is provided for free). As shown in other countries, evaluating
the cost of diagnosing and treating leishmaniasis and its financial impact on society may help
bringing this disease out of the neglect and trigger research to implement new clinical manage-
ment options [8,9]. In fact, despite the relatively contained number of cases registered each
year, the complicated procedures needed for the detection of VL in endemic areas and the
expensive treatment of the severe cases, are likely to imply a relevant economic and financial
burden to the Moroccan health system. The objective of this study was to report the costs asso-
ciated to the clinical management of pediatric VL from the provider perspective in Morocco.
As a secondary objective we described the current clinical practices and the epidemiological
characteristics of pediatric VL patients. The results of this study in Morocco can be translated
to other countries in North Africa facing similar challenges.
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Methods
The costs associated to pediatric VL in Morocco were estimated using patient data gathered
from hospital records. Clinical and epidemiological data were also collected from those two
sources.
Hospital records
Selection of hospitals. We used the number of reported VL patients per province from
2003 to 2012 to select the 10 provinces with the highest case load in Morocco. The number of
VL cases per province was provided by the Ministry of Health. We then selected public hospi-
tals with a pediatric unit located in those provinces or in the surrounding area. We assumed
that those hospitals would treat VL patients regularly as they are located in the L. infantum
endemic region in Morocco.
Data collection. The selected hospitals were visited fromMarch to June 2014. The avail-
able medical records from VL patients treated in each hospital in recent years (2009 to 2014)
were retrieved. A pro-forma was used to collect 1) demographic (e.g. age, gender) and 2) clini-
cal and 3) management data. The data collected included information on laboratory (e.g. com-
plete blood count, serum creatinine, serum amylase and electrolytes), diagnostic (e.g. serology
and parasitology) and other tests (e.g. x-rays, echography) performed to each patient and drugs
used. We collected individual information on the diagnostic procedure (e.g. Bone Marrow
Aspiration, ELISA) and treatment (e.g. number of injections of Glucantime) for VL. Relevant
dates (e.g. date when symptoms started, date of admission, date when VL treatment started
and ended, date of release) were also noted and used to estimate the days of hospitalization and
the delay in starting VL treatment after admission.
For each episode of VL, we recorded which tests were performed in the hospital and which
were performed in private institutions. When available, the outcome of the VL treatment was
also recorded. When the VL treatment was not completed at the hospital, we estimated the
number of doses the patient received at the primary health center (PHC) assuming a complete
treatment of 20 doses [2].
Cost estimation. The information retrieved from records was used to estimate direct costs
from the healthcare provider perspective. Individual records included the use of resources for
the management of the VL episode. Costs were estimated by multiplying the use of resources
in terms of number of days in hospital, tests performed and drugs provided in the public hospi-
tal by the official prices (unit costs) published by “L’Agence Nationale de l’Assurance Mala-
die”[10]. We assumed that the costs of all the drugs prescribed in the hospital were covered by
the Ministry of Health. Differences in unitary costs (e.g. cost of hospitalization) between
Regional and Provincial (CHR/P) and University (CHU) hospitals were taken into account.
Hospitalization cost consisted of equipment, infrastructure, overhead costs, and personnel
costs and these were already included in the official rate of day of hospitalization. We calcu-
lated the costs of tests conducted in the hospital and those performed in private laboratories or
health facilities. To estimate the unit costs of the tests (e.g. VL serology, X-rays) performed in
the private sector we used the prices applied in 4 private laboratories in Fez and Taza.
We specifically evaluated the costs of diagnosing and treating VL and differentiate them
from other laboratory tests and drugs. VL treatment cost was calculated based on the cost per
vial of Glucantime applied at the CHU in Fez: 1.70 US dollars (US$). We assumed that each
day of treatment (each injection) required one single use vial of Glucantime. The personnel
cost for the administration of Glucantime in the hospital was included in the hospitalization
cost. For Glucantime treatments provided at the PHC (outpatient treatment), we assumed a
cost of 0.90 US$ per injection, which included the wage of a nurse (5 minutes per treatment).
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Nurse’s time was valued based on the salary of a state-licensed nurses principal-mid grade
(1,733.26 US$/month [11]). Recurrent non-medical and capital costs at the PHC were not
taken into account. The complete list of resources and unit costs used in this study is provided
as supplementary material (S1 Table).
Analysis
VL patients. Only the data from pediatric patients for whom we had confirmed diagnosis
of VL (i.e. bone marrow aspirate and/or serology) and/or a record of anti-leishmanial treat-
ment (i.e. Glucantime injections) were included in the analyses. The demographic (e.g. age,
gender) and clinical data were used to describe the study population and the differences in clin-
ical management of VL patients. The clinical data analyzed included the diagnosis and treat-
ment of VL as well as clinical management indicators: days of hospitalization, tests to monitor
patients (e.g. ALT, Blood count tests, electrocardiography (ECG), X-rays) and other treatments
received (e.g. transfusions, antibiotics). The number of Glucantime doses provided at the PHC
were used to determine the treatment strategy used in different hospitals. Hospitals where
more than 70% of the patients received most of their VL treatment (more than 60% of the Glu-
cantime doses: 14 to 21 injections) at the PHC were defined as hospitals using an ambulatory
or out-patient care strategy. The rest used a hospital based or inpatient strategy. The results
were presented per hospital, by treatment strategy (e.g. inpatient vs outpatient) and for the
whole study population. Interquartile ranges (IQR) and 95% confidence intervals were calcu-
lated and presented when appropriate.
VL management costs. All costs were calculated in Moroccan Dirhams (MAD) and later
converted to 2014 US$ [12]. Costs were adjusted by applying a discount rate of 3% and cor-
rected by the annual inflation index [13].
The costs of VL management were divided into 5 cost categories: (1) diagnostic VL, (2)
treatment VL, (3) Hospitalization, (4) tests performed (e.g. Blood count, ECG) and (5) drugs
(other than anti-leishmanial) administered. The costs of VL diagnosis and tests were divided
between those conducted in the hospital and those performed in private facilities. The costs of
VL treatment were divided between those in the hospital and those in the PHC. Finally, tests
and drugs were combined to estimate the mean cost of a day in hospital. This value encom-
passed all costs of managing a pediatric VL episode in hospital excluding those specifically
related to diagnosis and treatment of VL.
All resources used as part of the management of pediatric VL were considered as financial
costs covered by the healthcare provider. The diagnostic tests performed at private health facili-
ties, initially paid by households, should be refunded by the national health insurance. Two dif-
ferent cost scenarios were constructed. Scenario 1 considered the use of public resources at
their public unit price and the use of private resources at their respective private unit price; and
scenario 2 considered both the public and private resources at their public unit price, as if all
test done at private health facilities were carried out in public health facilities. Scenario 2
implied that financial and economic costs are equal and represented the cost of VL manage-
ment if all resources used were conducted in public hospitals. In this manuscript we present
the results of scenario 1. Scenario 2 is presented as supplementary material (S3 Table). The cost
data is presented as median and inter-quartiles for both VL treatment strategies: inpatient vs
outpatient.
Statistical analyses. The non-parametric testMann-Whitney-Wilcoxon was used to iden-
tify statistically significant differences between inpatient and outpatient strategies. The sample
power was retrospectively estimated using bootstrapping methods [14]. Pearson's coefficient of
correlation was used to identify association among cost categories.
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A univariate sensitivity analysis was carried out to assess the robustness of results by chang-
ing values of three key parameters within plausible ranges. We evaluated the changes in the
median cost of diagnosing and treating a VL case when (1) the discount rate applied was either
0% or 5%, (2) the cost of a vial of Glucantime varied from 1.2 US$ (official price negotiated by
WHO [7]) to 3.4 US$ [15] and (3) when the salary of the nurse administering Glucantime at
the PHC ranged from principal-low grade (US$ 1,186.83/month) to principal-high grade (US$
1,895.00/month) [11]. Modifying the nurse’s salary resulted in varying the cost of administer-
ing Glucantime at PHC from US$ 0.62 to US$ 0.99 per treatment. We use a tornado diagram
to present the results of the sensitivity analysis. The analyses were performed in stata v10 (Sta-
taCorp) and Excel (Microsoft).
Ethical considerations
The study protocol was approved by the Comité d’éthique du CHU Hassan II in Fes (Morocco)
and Comité Ético de Investigación Clínica del Hospital Clínic de Barcelona (Spain). The clini-
cal data from patients were anonymized: no names, addresses or any other information allow-
ing the identification of individuals were recorded.
Results
Hospitals surveyed
The ten provinces with the highest VL case load from 2003 to 2012 are presented in Fig 1.
Those provinces account for more than 76% (1051/1370) of VL cases reported in Morocco
from 2003 to 2012. This is the highest endemic area for VL in Morocco as described by other
authors previously [1,3]. Eight hospitals with a pediatric unit were identified in the region (Fig
1). One was a University Hospital (Centre Hospitalier Universitaire–CHU), four were regional
(CHR) and three were provincial (CHP) hospitals. We did not find any medical records of VL
patients in one of the hospitals, thus the analyses were conducted on data retrieved from the
remaining 7.
VL patients
Out of the 131 clinical records obtained four were excluded as there was no information on
diagnosis or treatment of VL. Table 1 details the demographic and VL clinical management of
the 127 VL patients finally retained for the analyses. Briefly, the number of clinical records
retrieved from the 7 hospitals ranged from 9 to 37. The 127 VL patients had a mean age of 2.9
and half of them were males (49.6%). Based on the data available (n = 97), pediatric patients
had mean weight of 11.4 kg (SD = 4.8). The distribution of patients per weight is provided as
Supplementary material (S2 Table). Five patients (3.9%) could be considered treatment
Fig 1. (A) Map of North Morocco showing the distribution of visceral leishmaniasis (VL) cases reported per
province from 2003 to 2012. (B) The ten provinces with the highest number of VL cases reported from 2003 to
2012 highlighted in red and the 8 Hospitals selected for the cost study identified with a star. Map generated
with QGIS 2.2.0-Valmiera and geographical data from GADM (http://www.gadm.org/).
doi:10.1371/journal.pone.0155482.g001
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failures. Of them, four (3.1%) had to receive more than one Glucantime treatment and one
(0.8%) died during treatment. However most of the records did not have information on the
final outcome. None of the 127 VL cases was treated with Liposomal Amphotericin B, the sec-
ond line treatment in Morocco.
The diagnosis and treatment of VL also varied in the 7 hospitals included in the study. The
bone marrow aspirate was used as diagnostic tool in 71.7% of the patients but in some hospitals
this diagnostic method was only used in less than 10% of the patients (e.g. 7.7% in hospital
number 5). Serological tests were used in half of the patients (52.0%), but its implementation
varied with the hospital (range 17.6 to 92.3%). Finally both serological and parasitological tests
Table 1. Demographic Information and data on diagnosis and treatment procedures to manage pediatric visceral leishmaniasis (VL) in Morocco.
Data extracted from 127 clinical records in 7 hospitals in Morocco. Mean and 95%Confidence Intervals (CI), Median and Interquartile Range (IQR) or per-
centages are used when appropriate.
Demographic
information
Diagnosis Visceral Leishmaniasis VL Treatment with Glucantime
Age
(years)
Gender Serology Parasitology Both
Tests
Total
Doses
Doses
Hospital
Doses
PHC
Outpatient
Patients
Hospital N Mean
(95% CI)
% males /
% females
% (95% CI) % (95% CI) % (95%
CI)
Median
(IQR)
Median
(IQR)
Median
(IQR)
%
1 12 2.1 (1.3–
2.9)
25.0 / 75.0 91.7 (61.5–
99.8)
83.3 (51.6–
97.9)
75.0
(42.8–
94.5)
24.0 (24.0–
25.5)
17.0
(12.0–
24.0)
9.5 (2.5–
13.0)
25%
2 26 3.3 (2.2–
4.4)
44.0 / 66.0 73.1 (52.2–
88.4)
76.9 (56.4–
91.0)
53.8
(33.4–
73.4)
21.0 (21.0–
21.0)
9.0 (8.0–
11.0)
12.5
(11.0–
14.0)
27%
3 9 4.5 (1.3–
7.8)
55.6 / 44.4 66.7 (29.9–
92.5)
44.4 (13.7–
78.8)
33.3
(7.5–
70.1)
21.0
(21.0.21.0)
20.0
(10.0–
21.0)
0.0 (0.0–
11.0)
11%
4 13 2.8 (2.0–
3.6)
33.3 / 66.7 30.8 (9.1–
61.4)
92.3 (64.0–
99.8)
23.1
(5.0–
53.8)
20.0 (20.0–
21.0)
20.0
(20.0–
21.0)
0.0 (N/A) 0%
5 13 3.5 (1.4–
5.6)
61.5 / 38.5 92.3 (64.0–
99.8)
7.7 (0.2–36.0) 0.0 (N/A) 34.0 (28.0–
34.0)
34.0
(28.0–
34.0)
0.0 (0.0–
0.0)
15%
6 37 2.3 (1.6–
2.9)
51.4 / 48.6 29.7 (15.9–
47.0)
86.5 (71.2–
95.5)
21.6
(9.8–
38.2)
21.0 (21.0–
21.0)
5.0 (3.0–
7.0)
16.0
(14.0–
18.0)
86%
7 17 2.8 (1.3–
4.2)
73.3 / 26.7 17.6 (3.8–
43.4)
70.6 (44.0–
89.7)
11.8
(1.5–
36.4)
21.0 (21.0–
21.0)
6.0 (2.0–
9.0)
15.0
(12.0–
19.0)
71%
Total 127 2.9 (2.4–
3.3)
49.6 / 50.4 52.0 (42.9–
60.9)
71.7 (63.0–
79.3)
30.7
(22.8–
39.5)
21.0 (21.0–
21.0)
9.0 (6.0–
20.0)
12.0 (0.0–
17.0)
45%
Strategy
Inpatient 73 3.2 (2.5–
3.8)
43.7 / 56.3 71.2 (59.4–
81.2)
64.4 (52.3–
75.3)
39.7
(28.5–
51.9)
21.0 (21.0–
24.0)
16.0 (9.0–
21.0)
8.0 (0.0–
13.0)
18%
Outpatient 54 2.4 (1.8–
3.0)
57.7 / 42.3 25.9 (15.0–
39.7)
81.5 (68.6–
90.7)
18.5
(9.3–
31.4)
21.0 (21.0–
21.0)
5.0 (3.0–
7.0)
16.0
(14.0–
18.0)
81%
MWW P-value
In vs out-patient
0.0166 0.1257 <0.0001 0.0353 0.0107 0.0080 <0.0001 <0.0001
Test power 67.2% 32.4% 99.9% 55.4% 74.3% 77.9% 100% 100%
Note: Mann-Whitney-Wilcoxon (MWW) null hypothesis of no differences between inpatient and outpatient strategies.
doi:10.1371/journal.pone.0155482.t001
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were used to diagnose VL in almost one-third (30.7%) of the patients. None of the 7 hospitals
had the capacity to conduct serological tests for leishmaniasis at the time of the survey. All
serological tests were conducted in private laboratories and were paid by the patient’s relatives.
Out of the 66 patients with serological tests, 59 had a result in the clinical records and 58 of
them were positive (98%). The serological tests used were ELISA (65%) or IFI (33%). Rapid
diagnostic tests were not applied in any of patients. The majority of parasitological tests (64% -
58/91) were conducted in the hospital. The rest (31/91–34%) of the patients had their bone
marrow aspirates tested in private laboratories and 2 patients had parasitological results from
both the hospital and private laboratories. The majority of the records (80/91) had information
on the results of the parasitological test; 87.5% of them (70/80) were positive. In 33 patients we
had both serological and parasitological results.
The total number of Glucantime doses was calculated assuming that patients treated in the
PHC received the complete treatment. Thus most of the patients in the study received 20 to 21
doses in total. This may be a conservative estimate as there were two hospitals where patients
received more doses of Glucantime (e.g. 24 and 34 in hospitals 1 and 5 respectively). In these
hospitals Glucantime treatment was longer as the drug was given at progressive doses for 3 to 6
days before starting the standard treatment at 20 mg Sbv/kg. In one of these hospitals, Glucan-
time at therapeutic doses was usually given for 28 days instead of 20 as indicated in the guide-
lines. When the 127 records were considered, patients seem to receive more Glucantime doses
at the PHC (median = 12) than in the hospital (median = 9). However these figures were highly
dependent on the strategy used by the hospital. In hospitals using an inpatient approach (hos-
pitals 1 to 5), most of the Glucantime doses were provided in the hospital (median = 16). In
hospitals applying an outpatient strategy, only one fifth (median = 5) of the doses were given at
the hospital.
The strategy applied to treat VL patients had an impact on the clinical management indica-
tors presented in Table 2. The total days of hospitalization, days from admission to treatment
and days of treatment were significantly higher in hospitals using an inpatient approach com-
pared to those applying an outpatient strategy. Similarly, the number of tests (e.g. blood counts,
liver and kidney function tests), number of blood transfusions per patient and the proportion
of patients receiving antibiotics were significantly higher in hospitals using an inpatient
approach. These differences were statistically significant (Table 2). The majority of patients
(85/127–67%) had to conduct at least one test in a private laboratory. This proportion increases
to 77% (98/127) if diagnostic tests for VL are also considered. These factors have an impact on
the monitoring of VL patients under treatment and the costs associated to the clinical manage-
ment of VL.
VL management costs
As shown in Table 3, the median cost of managing a pediatric VL case in Morocco was US$
520 (mean of US$ 594). More than half of it (US$ 262) corresponded to hospitalization costs
which were strongly correlated to the number of days in hospital (Pearson correlation coeffi-
cient of 0.98). Fifteen percent of the costs were related to diagnosis and treatment of VL (US$
87). The rest (33%) were costs related to treatments and tests not directly attributable to VL
(US$ 133). The majority of the costs (90%) derived from the use of public resources, most of
them in the hospital (US$ 440) and only a 5% at the PHC (US$ 31). The other 10% of the costs
corresponded to out-of-pocket expenditures initially paid by the patients’ relatives (US$ 49).
These costs are in theory reimbursed by the national health insurance.
Cost differed with the VL treatment strategy. The total cost, as well as costs of VL diagnosis,
hospitalization and other treatments were significantly lower in hospitals applying an
Cost of Pediatric Visceral Leishmaniasis Care in Morocco
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outpatient strategy compared to inpatient hospitals (Table 3). The median cost per patient in
hospitals following an inpatient approach increased a 22% (US$ 636) compared to the pooled
estimate. The cost per patient using an outpatient strategy was 41% lower (US$ 307). VL diag-
nosis costs were higher in inpatient hospitals (US$ 40) as the large majority of tests to diagnose
VL were conducted in private facilities. In contrast in hospitals applying an outpatient
approach the VL diagnosis was mainly done in hospital facilities and the overall cost of this cat-
egory was lower (US$ 23). The treatment of VL was higher in hospitals were patients received
most of the treatment at the PHC (US$ 52) compared to inpatient hospitals (US$ 47) as the
cost of VL treatment at PHC included the cost of administering Glucantime. The hospitaliza-
tion costs were more than two times higher in inpatient (US$ 357) than outpatient (US$ 154)
hospitals. However, in both strategies these costs represent 52% of the total costs. The cost of
tests (other than VL diagnosis) represented 24% in inpatient care compared to 12% using out-
patient approach. Bootstrap methods confirmed that results assessed the highest level of power
on all comparisons undertook (Table 3).
The median cost of a day in hospital was US$ 32 (mean of US$ 33) when the data from all
hospitals was pooled together. This cost was significantly higher in hospitals following an
Table 2. Demographic and clinical information extracted from the clinical records of 127 visceral leishmaniasis (VL) patients in Morocco. Data
related to the clinical management of VL patients: days in hospital, days of VL treatment, number (Num.) of tests (e.g. blood counts, ALT or BUN) and blood
transfusions per patients as well as the proportion of patients receiving antibiotics are presented. These are just a fraction of the parameters considered in the
cost analysis. The data is presented aggregated (1) per hospital, (2) for the whole population and (3) by treatment strategy (inpatient vs outpatient). Mean and
95%Confidence Intervals (CI) or Median and Interquartile Range (IQR) are used when appropriate. Hospitals are identified with numbers.
Days in
hospital
Days to
treatment
Days of
treatment
Num. Blood
Counts
Num. ALT1
tests
Num. BUN2
tests
Num.
Transfusions
Patients with
antibiotics
Hospital N Median
(IQR)
Median (IQR) Median (IQR) Mean (95%
CI)
Mean (95%
CI)
Mean (95%
CI)
Mean (95% CI) % (95% CI)
1 12 28.5 (19.5–
31.0)
9.5 (6.0–13.0) 16.5 (12.0–
24.5)
11.4 (6.6–
16.3)
6.0 (2.3–
9.7)
9.1 (2.0–
16.2)
0.9 (0.6–1.0) 100.0 (73.5–
100.0)
2 26 15.0 (12.0–
19.0)
no data no data 3.1 (2.6–3.6) 1.4 (1.1–
1.7)
1.5 (1.3–1.8) 0.8 (0.6–0.9) 88.5 (69.8–97.6)
3 9 20.0 (15.0–
25.0)
3.0 (0.0–5.0) 20.0 (9.0–
22.0)
1.1 (0.3–1.9) 0.4 (0.0–
0.8)
0.1 (0.0–0.4) 0.4 (0.1–0.8) 44.4 (13.7–78.8)
4 13 23.0 (22.0–
25.0)
3.0 (2.0–7.0) 19.0 (17.5–
20.0)
1.9 (1.2–2.6) 0.3 (0.0–
0.7)
0.5 (0.1–0.9) 0.7 (0.4–0.9) 76.9 (46.2–95.0)
5 13 34.0 (31.0–
40.0)
5.0 (4.0–7.0) 32.0 (27.0–
33.0)
1.8 (1.2–2.4) 2.0 (1.3–
2.7)
1.8 (1.1–2.6) 0.2 (0.1–0.5) 61.5 (31.6–86.1)
6 37 6.0 (3.0–
8.0)
1.0 (1.0–2.0) 4.0 (2.0–6.0) 0.9 (0.7–1.1) 0.1 (0.0–
0.1)
0.2 (0.1–0.4) 0.4 (0.2–0.6) 24.3 (11.8–41.2)
7 17 7.0 (2.0–
21.0)
1.0 (1.0–2.0) 7.0 (2.0–20.0) 1.7 (1.1–2.3) 0.2 (0.0–
0.6)
0.5 (0.1–0.9) 0.4 (0.1–0.6) 64.7 (38.3–85.8)
Total 127 14.0 (7.0–
23.0)
2.0 (1.0–6.0) 8.0 (4.0–20.0) 2.7 (2.0–3.3) 1.2 (0.7–
1.6)
1.6 (0.8–2.3) 0.5 (0.5–0.6) 60.6 (51.6–69.2)
Strategy
Inpatient 73 21.0 (15.0–
30.0)
5.5 (2.0–8.0) 20.0 (12.0–
31.0)
3.8 (2.7–4.9) 1.9 (1.2–
2.7)
2.5 (1.2–3.7) 0.7 (0.5–0.8) 78.1 (66.9–86.9)
Outpatient 54 6.0 (3.0–
9.0)
1.0 (0.0–2.0) 4.0 (2.0–7.0) 1.1 (0.9–1.4) 0.1 (0.0–
0.2)
0.3 (0.1–0.5) 0.4 (0.3–0.5) 37.0 (24.3–51.3)
MWWP-value In
vs out-patient
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Test Power 100% 100% 100% 100% 100% 100% 93.7% 99.9%
Note: Mann-Whitney-Wilcoxon (MWW) null hypothesis of no differences between inpatient and outpatient strategies. 1 alanine aminotransferase (ALT)
test to evaluate liver function. 2 blood urea nitrogen (BUN) test to evaluate kidney function.
doi:10.1371/journal.pone.0155482.t002
Cost of Pediatric Visceral Leishmaniasis Care in Morocco
PLOS ONE | DOI:10.1371/journal.pone.0155482 June 3, 2016 8 / 13
outpatient approach US$ 36 (mean of US$ 39) compare to inpatient hospitals US$ 28 (mean of
US$ 29) (Table 3).
When the use of all private resources was estimated at public unit price (scenario 2) the
total median cost per VL patient was US$ 486 (mean of US$ 571). The differences between VL
treatment strategies were similar to those observed in scenario 1 (S3 Table).
The sensitivity analysis (Fig 2) showed that modifying the salary of the nurse at the PHC
had a limited impact on the median cost per VL episode. However, doubling the cost of Glu-
cantime increased the cost per VL case to US$ 560. Reducing the discount rate from 3% to 0%
would increase the median cost per VL episode to US$ 538, while a discount rate of 5% would
reduce the costs to US$ 479.
Discussion
The median cost of diagnosing and treating a pediatric case of visceral leishmaniasis in
Morocco is US$ 520. Our estimate is lower than the cost of treating a pediatric VL patient with
Glucantime in Greece (935.6 to 1639 euros) [16] or in Italy (over 3000 euros) [17]. To our
knowledge there are no other cost studies for VL in North Africa. In Morocco, the studies on
Table 3. Costs of pediatric visceral leishmaniasis (VL) care in Morocco (US$). Total costs and costs divided by category (VL diagnosis, VL treatment,
Hospitalization, Tests and other Treatments) presented for the whole study population and per treatment strategy: inpatient and outpatient. Mean, standard
deviation (sd), median, inter-quartile range (IQR) are presented for each category, as well as p-values associated to Mann-Whitney-Wilcoxon (MWW) test
and bootstrapping results for assessing the level of power on the comparisons.
Total (N = 127) Inpatient (N = 73) Outpatient (N = 54)
Mean (sd) Median (IQR) % Mean (sd) Median (IQR) % Mean (sd) Median (IQR) % MWW
Pvalue
Test
power
VL diagnosis 42 (26) 38 (22–
58)
7% 51 (27) 40 (36–
75)
6% 30 (20) 23 (21–
40)
10% <0.001 100%
Hospital 11 (12) 0 (0–22) 2% 5 (9) 0 (0–0) 0% 19 (11) 22 (21–
23)
6%
Private 31 (30) 36 (0–40) 5% 46 (29) 39 (36–
75)
6% 11 (17) 0 (0–36) 4%
VL treatment 49 (10) 49 (45–
53)
8% 47 (12) 47 (39–
52)
6% 51 (5) 52 (49–
54)
16% 0.003 84.2%
Hospital 21 (16) 15 (10–
34)
3% 29 (16) 27 (15–
36)
4% 11 (9) 9 (5–13) 4%
PHC 27 (19) 31 (0–44) 5% 18 (18) 21 (0–34) 2% 40 (13) 43 (37–
49)
12%
Hospitalization 309 (236) 262 (161–
376)
52% 415 (251) 357 (273–
464)
52% 165 (99) 154 (95–
214)
52% <0.001 100%
Tests 148 (369) 75 (30–
128)
25% 228 (472) 116 (84–
186)
29% 40 (34) 35 (13–
60)
12% <0.001 100%
Hospital 120 (351) 48 (12–
97)
20% 187 (452) 85 (39–
142)
24% 28 (26) 23 (7–45) 9%
Private 28 (39) 13 (0–40) 5% 40 (45) 22 (4–64) 5% 11 (18) 0 (0–17) 3%
Other treatment 47 (40) 58 (4–73) 8% 57 (41) 64 (8–87) 7% 34 (34) 21 (3–62) 10% <0.001 96.9%
Total Costs 594 (544) 520 (316–
658)
798 (637) 636 (548–
825)
319 (134) 307 (216–
416)
<0.001 100%
Cost of a day in
hospital*
33 (13) 32 (22–
40)
29 (10) 28 (19–
38)
39 (15) 36 (29–
45)
<0.001 97.3%
Note: VL treatment at the PHC consisted of the price of Glucantime and the personnel cost of the injection; capital and recurrent costs could not be
estimated. VL treatment at the hospital included only the price of Glucantime as personnel, capital and recurrent costs were included in the category
“hospitalization”.
*This is the cost of a day in hospital excluding the costs of the diagnostic tests (e.g. serology, bone marrow aspirate) and treatments (e.g. glucantime)
speciﬁc to visceral leishmaniasis management.
doi:10.1371/journal.pone.0155482.t003
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the cost of infectious diseases are scarce. Using a chronic disease as a reference; the cost of lung
cancer management in Morocco is estimated to range between US$ 3,420 and 4,600 per year
[18]. The limited cost of VL management and the low prevalence of this disease in Morocco
should allow providing the best standards of care to all children suffering from VL.
An increase in discount rate from 3% to 5% and an increase in Glucantime price for injec-
tion from 1.2 to 3.4 US$) had an impact higher than 5% over the total median cost per VL case.
All other variations applied to parameters for sensitivity analysis led to shifts in the median
costs lower than 5%. For example, adopting no discount (discount rate of 0%) implied a cost
increase of about 3.5%. The small variation could be explained by the relatively short time hori-
zon of the analysis, 6 years.
The economic burden of VL management from a societal perspective is likely to be signifi-
cantly greater as the households costs associated to VL treatment (e.g. indirect medical costs,
transport, loss of income to the attendant), not included in the current analysis, may be rele-
vant [9]. In Morocco the diagnosis and treatment are covered by the MoH but this study
shows that in some hospitals some tests (e.g. blood count, x-rays, ECG) are conducted out-
side the hospital facilities. In particular, none of the hospitals in the study had the capacity to
conduct serological tests for VL. This increased the cost of VL management as patient’s had
to submit their samples or conduct their tests in external private laboratories. If those tests
were carried out in public health facilities (scenario 2) the median cost per VL patient would
be US$ 486.
Fig 2. Tornado diagram presenting the results of the univariate sensitivity analysis. Changes on the median cost per pediatric Visceral
Leishmaniasis (VL) patient were evaluated by shifting (1) the discount rate (from 0% to 5%, base case %), (2) the cost of a vial of Glucantime (from US$
1.2 to US$ 3.4, base case US$ 1.70) and (3) the cost of administering Glucantime at the Primary Health Centre (PHC) (from US$ 0.62 to US$ 0.99,
base case US$ 0.90).
doi:10.1371/journal.pone.0155482.g002
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More importantly our study shows that two VL treatment strategies are applied in Morocco.
Most of the patients receive their complete VL treatment in the hospital but a significant num-
ber of VL cases receive part of their Glucantime injections as outpatients in the PHC. These dif-
ferent approaches have a profound effect on the cost of VL management as the outpatient
strategy reduces significantly, among others, the hospitalization costs. It also reduces de costs
associated to laboratory and other tests (e.g. blood count, hepatic function) which are related to
the monitoring of the VL cases. The outpatient strategy, which is less expensive to the provider
(US$ 307) has been suggested as an alternative to inpatient VL treatments in children in Greece
[9]. A small study (n = 20 children) showed that the outpatient care seems to be safe and effec-
tive [19] and 27% cheaper (1639 vs 935.6 euros) than the inpatient strategy [16]. However pedi-
atricians in Italy are against the outpatient administration of antimonials as it requires a close
monitoring (e.g. fatal toxicities) [17]. Furthermore, this strategy is not recommended as VL
treatment for children in the WHO [7] or the Moroccan [2] guidelines. The efficacy and safety
of outpatient strategy in Morocco should be evaluated. Until then, the inpatient strategy rec-
ommended by the national guidelines [2], which is 35% more expensive (US$ 636), may be
used as a reference.
Our study reports other important differences between hospitals: total days of hospitaliza-
tion, time to VL diagnosis, duration of the treatment, etc. Some of these differences are due to
variability among cases (e.g. severe cases require longer hospitalizations, closer monitoring)
but others are related to differences in management and hospital facilities. For example, none
of the hospitals could diagnose VL with serological tests but hospitals that have an easy access
to MoH laboratories diagnosing VL from BM aspirates (e.g. Hospital number 6) have a reduced
time to VL diagnosis (median 1 day). In some hospitals pediatricians apply treatment regimens
not recommended by the national guidelines (e.g. progressive doses, 28 days treatment) which
increase the days in hospital. It should be noticed that the recommended treatment for VL in
Morocco is a shorter (Glucantime for 20 days) than the regimen suggested by the WHO (Glu-
cantime for 28 days) [7]. This shorter regimen was incorporated in the national guidelines in
2010 after an expert consultation led by the Ministry of Health (Laamrani personal communi-
cation). Longer treatments of Glucantime (up to 28 days) can be administered if necessary [2].
In this study we did not compare the cost of short (20 doses) and longer (28 doses) glucantime
treatments. Data on efficacy (e.g. relapses at 6 months) which are currently not available in
most of the cases would allow estimating the cost-effectiveness of the different treatments and
strategies. Access to VL diagnosis and treatment regimens should be standardized following
the current guidelines in Morocco [2].
This cost study is based on a cohort of 127 VL patients treated in 7 hospitals. These hospitals
were selected as they are in the VL endemic area in Morocco [3]. However there are sporadic
VL cases reported in other provinces e.g. 24% (n = 319) of the VL cases recorded from 2003 to
2012. Those patients may be diagnosed and treated in hospitals not included in our study. As
we could not visit all the hospitals in Morocco we selected those serving the VL endemic area.
It is difficult to predict the effect of including hospitals from other provinces in our cost esti-
mates. Those hospitals may diagnose and treat VL cases sporadically. The number of cases
(n = 127) included in the study approximately corresponds to the annual incidence of VL in
Morocco. The mortality and treatment failure estimates from this cohort (0.8% and 3.1%
respectively) are similar to those reported in case series studies in Morocco and other countries
in the area [5,6]. However they need to be interpreted with caution as information on the out-
come was missing in all the cases referred to the PHC for outpatient treatment and none of the
cases records evaluated had follow-up information at 6 months post-treatment as required by
WHO guidelines [7]. The number of medical records retrieve per hospital was also variable.
Some had an efficient records system (e.g. Hospital number 2) but others were less well
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organized, e.g. one hospital had to be excluded as no VL records were found. Improving and
standardizing the hospital records archives and databases would allow conducting retrospec-
tive studies more efficiently. Despite some information was missing in the registries, the main
strength of this cost study is the use of patient level data which allowed micro-costing, a more
precise approach compared with others (top-down for instance) through which variability of
resources used is well represented. As a result, our study provides valuable economic estimates
as well as clinical and management information. These data should help health managers in
Morocco and other countries in the region improving the management of VL in children.
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